Healthy
Conditions
Keywords
oxytocin, vasopressin, delta-beta coupling
Brief summary
The main aim of the study is to investigate whether intranasal oxytocin and vasopressin have effects on delta-beta cross-frequency coupling under resting-state and task conditions.
Detailed description
A double-blinded, placebo-controlled, between-subject design is employed in this study. In a randomized order, a total of 120 healthy males and females are instructed to self-administer intranasal spray of oxytocin, vasopressin, or placebo. (1) 15-minute resting-state EEG data are collected 35 minutes after treatment. (2) Participants complete tasks including Stroop, GO/NOGO, and anxiety induction with behavioral (response time, accuracy, or rating) and EEG data being collected. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), and Adult ADHD Self-Report Scale (ASRS-v1.1). Participants are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before resting state and after the tasks. Three blood samples (5 ml) are collected into 6 ml ETDA tubes when participants just arrive, before resting state recording and after all of the tasks.
Interventions
Subject assigned to receive intranasal administration of oxytocin (24 IU).
Subjects assigned to receive intranasal administration of vasopressin (20 IU).
DRUGIntranasal Placebo
Subjects assigned to receive intranasal administration of placebo.
Sponsors
University of Electronic Science and Technology of China
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy subjects without past or current psychiatric or neurological disorders.
Exclusion criteria
* History of head injury. * Pregnant,menstruating,taking oral contraceptives. * Medical or psychiatric illness.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Resting-state EEG | 35-50 minutes after treatment administration. | Participants are asked to sit comfortably and look at a white cross fixation against a black background on the computer monitor for 15 minutes with delta-beta cross-frequency coupling as a main index. |
| Behavioral indices in the tasks | 50-90 minutes after treatment administration. | Reaction time and accuracy are recorded in the emotional Stroop and Go/Nogo tasks. For the anxiety induction task, participants are instructed to rate their anxiety levels using a 9-point Likert scale within 4 seconds (1 = not at all, 9 = very anxious). |
| Task-based EEG | 50-90 minutes after treatment administration. | EEG data are recorded in the emotional Stroop, Go/Nogo, and anxiety induction tasks. Delta-beta cross-frequency coupling will be calculated to do statistical analyses. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SCR in anxiety induction | 70-90 minutes after treatment administration. | Skin Conductance Response (SCR) data are recorded in the anxiety induction task under safe and anxious conditions. |
Countries
China
Outcome results
None listed